[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"erosive-hand-osteoarthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:erosive-hand-osteoarthritis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100631501","phase-2-methotrexate-treatment-in-hand-osteoarthritis-refractory-to-usual-treatments-100631501",false,"NCT07501507","Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments","Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual Treatments: A Randomised, Double-blind, Placebo-controlled Trial","ADEM2","Inclusion Criteria:\n\n\\- Digital osteoarthritis (IPD and IPP) according to ACR criteria (with an X-ray of the hands taken less than 3 months ago, showing at least 3 joints with digital osteoarthritis KL\\>=2) and symptomatic for more than three months\n\nExclusion Criteria:\n\n* Having a bilirubin level \\> 5 mg\u002Fdl (85.5 µmol\u002Fl)\n* Pregnant or breastfeeding women (a urine pregnancy test will be performed on women of childbearing age),\n* Injection of hyaluronic acid within the previous 6 months,\n* Injection of cortisone derivatives within the previous 3 months,\n* Presence of psoriasis,\n* Inflammatory rheumatism,\n* Microcrystalline arthropathy,\n* Joint prosthesis in one of the joints of the hand,\n* Planned placement of a joint prosthesis in the hand during the study period,\n* Major progressive disease (life-threatening cardiovascular disease, hematopoietic cancers including myeloma, cancers with risk of bone metastases),\n* Liver failure.\n* Severe renal failure (creatinine clearance less than 50 ml\u002Fmin).\n* Positive hepatitis B serology.\n* Tuberculosis, hepatitis C, HIV positive, or other immunodeficiency syndromes.\n* Uncontrolled infections.\n* Use of corticosteroids.\n* Use of morphine derivatives,\n* Taking Bactrim,\n* Taking high doses of aspirin (greater than or equal to 500mg\u002Fday),\n* Contraindications to the use of methotrexate,","ALL","40 Years","85 Years",{"count":21,"type":22},170,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","Randomized study comparing the structural efficacy of methotrexate versus placebo in digital osteoarthritis",[29],"Erosive Hand Osteoarthritis","RECRUITING","2026-09-23",{"date":33,"type":34},"2026-09-24","ACTUAL",{"date":31,"type":34},{"date":37,"type":22},"2028-02",{"name":39,"class":40},"Centre Hospitalier Universitaire de Nice","OTHER"]